Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: A potential new marker

Gema Ariceta*, Ellen R Brooks, Craig Langman

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Elevated plasma B-type natriuretic peptide (BNP) level is a hallmark of altered left ventricular (LV) structure and function. Measurement of circulating BNP has proved to be a sensitive and specific diagnostic test for congestive heart failure (CHF) and coronary syndrome in adults. Further, BNP levels constitute a strong predictive marker for future cardiovascular (CV) events. In high CV risk populations, such as adults with hypertension or chronic kidney disease (CKD), increased BNP predicts CV morbidity and mortality in symptomatic or asymptomatic patients. However, caution is needed in interpreting plasma BNP levels, as they increase with both age and decreased renal function. Despite increasing evidence of the value of BNP in the medical literature in adults, data in children are limited to those with congenital heart disease. It is appropriate to analyze the potential application of this tool in children with CKD, a well-known factor for CV disease.

Original languageEnglish (US)
Pages (from-to)1701-1707
Number of pages7
JournalPediatric Nephrology
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2005

Keywords

  • Cardiac dysfunction
  • Congestive heart failure
  • Dialysis
  • Hypertension
  • Kidney transplant
  • Left ventricular hypertrophy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Fingerprint Dive into the research topics of 'Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: A potential new marker'. Together they form a unique fingerprint.

  • Cite this